Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IcoSema vs insulin icodec in type 2 diabetes (weekly dosing)
CTR20220768Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of icosema in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Apr 2022; status: completed.
02
Drugs
icosema
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20220768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220768.